JP2022521824A5 - - Google Patents
Info
- Publication number
- JP2022521824A5 JP2022521824A5 JP2021557651A JP2021557651A JP2022521824A5 JP 2022521824 A5 JP2022521824 A5 JP 2022521824A5 JP 2021557651 A JP2021557651 A JP 2021557651A JP 2021557651 A JP2021557651 A JP 2021557651A JP 2022521824 A5 JP2022521824 A5 JP 2022521824A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825450P | 2019-03-28 | 2019-03-28 | |
| US62/825,450 | 2019-03-28 | ||
| US201962842980P | 2019-05-03 | 2019-05-03 | |
| US62/842,980 | 2019-05-03 | ||
| US201962857519P | 2019-06-05 | 2019-06-05 | |
| US62/857,519 | 2019-06-05 | ||
| PCT/US2020/025539 WO2020198710A1 (en) | 2019-03-28 | 2020-03-27 | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022521824A JP2022521824A (ja) | 2022-04-12 |
| JP2022521824A5 true JP2022521824A5 (https=) | 2023-04-04 |
| JPWO2020198710A5 JPWO2020198710A5 (https=) | 2023-04-04 |
Family
ID=72610726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557651A Ceased JP2022521824A (ja) | 2019-03-28 | 2020-03-27 | アンドロゲン受容体の阻害剤を含む薬学的組成物及びその組み合わせならびにその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220202780A1 (https=) |
| EP (1) | EP3947353A4 (https=) |
| JP (1) | JP2022521824A (https=) |
| KR (1) | KR20210144827A (https=) |
| CN (1) | CN114502539A (https=) |
| AU (1) | AU2020248105A1 (https=) |
| CA (1) | CA3134545A1 (https=) |
| IL (1) | IL286726A (https=) |
| MX (1) | MX2021011826A (https=) |
| WO (1) | WO2020198710A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| WO2019226991A1 (en) | 2018-05-25 | 2019-11-28 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| US12030875B2 (en) | 2018-09-07 | 2024-07-09 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
| WO2020198712A1 (en) | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| AU2020348675B2 (en) | 2019-09-16 | 2025-11-20 | Takeda Pharmaceutical Company Limited | Azole-fused pyridazin-3(2H)-one derivatives |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| AU2021230289A1 (en) | 2020-03-03 | 2022-09-29 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| AU2021255723A1 (en) | 2020-04-17 | 2022-12-08 | Essa Pharma, Inc. | Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof |
| WO2022060969A1 (en) * | 2020-09-16 | 2022-03-24 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| KR20220111673A (ko) * | 2021-02-02 | 2022-08-09 | 주식회사 엘지화학 | 단백질 키나아제 억제제로서의 신규한 화합물 |
| WO2022221661A1 (en) * | 2021-04-16 | 2022-10-20 | Essa Pharma, Inc. | Pharmaceutical compositions comprising inhibitors of the androgen receptor and uses thereof |
| CN115340527B (zh) * | 2021-05-13 | 2023-09-15 | 成都先导药物开发股份有限公司 | 一种bcl-xl抑制剂及其制备方法和用途 |
| CN113603695B (zh) * | 2021-08-05 | 2022-06-14 | 青岛恒宁生物科技有限公司 | 一种取代的嘧啶胺类化合物或其作为农药可接受的盐、组合物及其用途 |
| JP2024534127A (ja) | 2021-08-25 | 2024-09-18 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| WO2023031371A1 (en) * | 2021-09-01 | 2023-03-09 | Janssen Pharmaceutica Nv | Combination therapies for metastatic castration-resistant prostate cancer |
| US20240358701A1 (en) * | 2021-09-01 | 2024-10-31 | Essa Pharma Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| CN118715210A (zh) * | 2022-02-10 | 2024-09-27 | 上海奕拓医药科技有限责任公司 | 雄激素受体活性调节剂及其应用 |
| CN117065033A (zh) * | 2022-05-17 | 2023-11-17 | 海创药业股份有限公司 | 一种治疗三阴乳腺癌的联合用药物 |
| WO2024006207A1 (en) * | 2022-06-26 | 2024-01-04 | Essa Pharma Inc. | An n-terminal domain androgen receptor inhibitor and uses thereof |
| US11993580B1 (en) | 2022-12-02 | 2024-05-28 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
| CN121698845A (zh) * | 2024-09-12 | 2026-03-20 | 青岛普泰科生物医药科技有限公司 | 一种四氢喹啉类ntd抑制剂及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2656842T (lt) * | 2006-03-27 | 2016-09-26 | The Regents Of The University Of California | Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui |
| WO2013028572A1 (en) * | 2011-08-19 | 2013-02-28 | British Columbia Cancer Agency Branch | Fluorinated bisphenol ether compounds and methods for their use |
| PT2872482T (pt) * | 2012-07-13 | 2020-09-22 | Oncternal Therapeutics Inc | Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm) |
| JP6884100B2 (ja) * | 2015-01-13 | 2021-06-09 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | がんの画像化及び治療用のヘテロ環式化合物ならびにそれらの使用方法 |
| US10980806B2 (en) * | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| US20170298033A1 (en) * | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| LT3474841T (lt) * | 2016-06-22 | 2022-06-10 | Ellipses Pharma Ltd | Ar+ krūties vėžio gydymo būdai |
| MX2021004427A (es) * | 2018-10-18 | 2021-11-12 | Univ British Columbia | Moduladores del receptor de andrógenos y métodos para su uso. |
-
2020
- 2020-03-27 CN CN202080039623.3A patent/CN114502539A/zh active Pending
- 2020-03-27 WO PCT/US2020/025539 patent/WO2020198710A1/en not_active Ceased
- 2020-03-27 MX MX2021011826A patent/MX2021011826A/es unknown
- 2020-03-27 KR KR1020217034804A patent/KR20210144827A/ko not_active Ceased
- 2020-03-27 JP JP2021557651A patent/JP2022521824A/ja not_active Ceased
- 2020-03-27 CA CA3134545A patent/CA3134545A1/en active Pending
- 2020-03-27 AU AU2020248105A patent/AU2020248105A1/en not_active Abandoned
- 2020-03-27 EP EP20779267.2A patent/EP3947353A4/en not_active Withdrawn
- 2020-03-27 US US17/599,338 patent/US20220202780A1/en not_active Abandoned
-
2021
- 2021-09-26 IL IL286726A patent/IL286726A/en unknown